160 related articles for article (PubMed ID: 21400027)
1. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells.
Staedler D; Idrizi E; Kenzaoui BH; Juillerat-Jeanneret L
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1161-72. PubMed ID: 21400027
[TBL] [Abstract][Full Text] [Related]
2. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
Akbas SH; Timur M; Ozben T
J Surg Res; 2005 May; 125(1):49-55. PubMed ID: 15836850
[TBL] [Abstract][Full Text] [Related]
3. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice.
Du G; Lin H; Yang Y; Zhang S; Wu X; Wang M; Ji L; Lu L; Yu L; Han G
Int Immunopharmacol; 2010 Jul; 10(7):819-26. PubMed ID: 20447470
[TBL] [Abstract][Full Text] [Related]
4. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells.
Chien SY; Wu YC; Chung JG; Yang JS; Lu HF; Tsou MF; Wood WG; Kuo SJ; Chen DR
Hum Exp Toxicol; 2009 Aug; 28(8):493-503. PubMed ID: 19755441
[TBL] [Abstract][Full Text] [Related]
5. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it.
Li S; Yuan S; Zhao Q; Wang B; Wang X; Li K
Biomed Pharmacother; 2018 Apr; 100():441-447. PubMed ID: 29475141
[TBL] [Abstract][Full Text] [Related]
6. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
7. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer.
Wang X; Kong L; Zhao J; Yang P
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):339-43. PubMed ID: 12408759
[TBL] [Abstract][Full Text] [Related]
10. Antigenotoxic effects of quercetin, rutin and ursolic acid on HepG2 cells: evaluation by the comet assay.
Ramos AA; Lima CF; Pereira ML; Fernandes-Ferreira M; Pereira-Wilson C
Toxicol Lett; 2008 Feb; 177(1):66-73. PubMed ID: 18276086
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
Ravid A; Rocker D; Machlenkin A; Rotem C; Hochman A; Kessler-Icekson G; Liberman UA; Koren R
Cancer Res; 1999 Feb; 59(4):862-7. PubMed ID: 10029076
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
14. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
15. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells.
Rama AR; Prados J; Melguizo C; Burgos M; Alvarez PJ; Rodriguez-Serrano F; Ramos JL; Aranega A
Biomed Pharmacother; 2011 Jul; 65(4):260-70. PubMed ID: 21723082
[TBL] [Abstract][Full Text] [Related]
17. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
19. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells.
Du G; Lin H; Wang M; Zhang S; Wu X; Lu L; Ji L; Yu L
Cancer Chemother Pharmacol; 2010 Jan; 65(2):277-87. PubMed ID: 19466611
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells.
Choi EJ; Bae SM; Ahn WS
Arch Pharm Res; 2008 Oct; 31(10):1281-5. PubMed ID: 18958418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
